Innovation in the Race to Develop COVID-19 Vaccines

Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market.

With multiple vaccines now approved and being manufactured in record time, we celebrate this accelerated pace of development in the field. Exploring the different vaccine technologies to understand their mode of action, benefits, risks, and potential real-life impact on protection. The challenges in manufacturing enough doses to vaccinate the world and the potential impact the WTO’s IP waiver proposal will have on future innovation.

Discussion Points:

  • Vaccine Science: Two Centuries of Continuous Research, Improvements, and Achievements
  • Future Potential of mRNA
  • Where are the facilities equipped for these new molecule types? What problems are arising and how is the industry working to fix them?
  • Vaccinating the world, a look at WTO’s proposed IP waiver and what it could mean for future innovation

This session was originally broadcast live as part of CPhI North America 2021.

Speakers Include:

  • Leonard Friedland, Vice President, Director Scientific Affairs and Public Health, GSK Vaccines
  • Fiona Barry, Associate Editor, Global Data
  • Dr Fintan Walton, CEO of PharmaVentures

Watch: Innovation in the Race to Develop COVID-19 Vaccines

Download Request

△ Legitimate business purposes include contacting me regarding PharmaVentures’ services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.

For further information on how PharmaVentures processes your data, please view our Privacy page.

How to achieve success in deal making

Hard lessons from 30 years of experience 

A conversation with Fintan Walton, Founder of PharmaVentures

Tony Jones, Chief Executive of One Nucleus, caught up with Fintan Walton to discuss the evolution of the deal making processes, where it is going in the future and what role PharmaVentures plays in deal making to support clients globally.

This insightful interview is useful to those new to deal making, but also interesting viewing for experienced deal makers who may recognise some of the situations they discuss, hard lessons from 30 years of experience.

How to achieve success in deal making

  • Learn the 3 key things you need in a successful transaction
  • What is the emotional aspect of deal making and what does the negotiator need to understand and recognise when they enter the meeting room?
  • How do you meet the biotech challenge – getting your voice heard by key decision makers within the pharmaceutical companies?
  • What are the key drivers for pharmaceutical companies when doing deals?
  • Gain insight into preparations for due diligence and negotiation

Hard lessons from 30 years of experience

  • Find out how the structures, dynamics and trends within deal making have evolved and how the marketplace has changed
  • Gain insight into how PharmaVentures’ experience and the time invested by the team to get to know their clients, makes a difference to the deal outcome
  • Understanding culture, language and having the experience for successful global deal making – critical resources PharmaVentures provides for its clients
  • Discover how PharmaVentures opens the doors for clients and how diversity within the team enables the company to reach out across cultures
  • When does PharmaVentures get into the valuation discussion on behalf of a client?

How to achieve success in deal making

Download Request

△ Legitimate business purposes include contacting me regarding PharmaVentures’ services, commercial opportunities in M&A, Licensing, Fundraising or similar on behalf of their clients or sending me marketing material related to relevant third-party events, products and services.

For further information on how PharmaVentures processes your data, please view our Privacy page.

How is M&A Shifting the Pharma Manufacturing Landscape?

Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape.

Partnerships and mergers are a key tool for adding value to pharmaceutical companies; helping to navigate technological limitations, address portfolio challenges and chase innovation.

This webinar, delivered in partnership with PharmaVentures, examines the trends and developments driving deal-making in the current market.

Chaired by Dr Fintan Walton, CEO & Founder of PharmaVentures, the panel included:

  • John P. FitzGerald, Senior Director, Business Development & Acquisitions, Abbvie
  • Andreas Raabe, Managing Partner & Founder, Adragos Pharma
  • William S. Marth, Managing Partner, North Ocean Ventures
  • Jansen Jacob, Vice President, PharmaVentures
  • Ozgur Akbulut, Director – Global Divestments and Contract Manufacturing Lead, Takeda

What the audience said:

“Great discussion, I wish it was 2 hours.”

“Thanks for the discussion, I also had the feeling we were just starting, so time flew by quickly! Very interesting and very professional speakers. Thanks.”

Watch: How is M&A Shifting the Pharma Manufacturing Landscape?

Download Request

Our Latest Videos

The Divestment Challenge

Watch Now

Contract Manufacturing in the Pharmaceutical Industry – Recipharm

Watch Now

Doing deals in the healthcare sector during the COVID-19 pandemic

Watch Now

White Papers

Deal Making in the Year of COVID-19

Read Now

Is Nationalism Transforming the Pharma Manufacturing Map

Read Now

M&A in COVID-19 Environment and Beyond – Keeping your perspective

Read Now

Manufacturing Operations Divestment Expertise

Having advised on the strategic direction of over 40 sites globally, we can help you to divest your manufacturing operations whilst safeguarding security of supply and retaining jobs, and assisting the new owners to build and grow profitable new businesses.

Our strategic reviews of operations have enabled our clients to engage us in the successful divestment of sites covering both small molecule and biologics capabilities across the globe.

Find out more

Special Edition: A Combined Fundraising & Partnering Strategy – a Better Way to Secure Success?

In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech.

Panelists include Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation at Novo NordiskJeanne Bolger, Vice President, Venture Investments at Johnson & Johnson InnovationBart Dzikowski, Managing Director, Head of Transactions & Legal at Novartis Venture FundTim Luker, Senior Director, External Innovation, Global External R&D at Eli Lilly and Company, and Kevin Johnson, Co-Founder at Medicxi.

Special Edition: A Combined Fundraising & Partnering Strategy – a Better Way to Secure Success?

Download Request

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.

Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in Israel, India, and North America. The company’s successful inorganic growth has been largely through the build and buy model of its founders, according to Marc.

They discuss the company’s current situation and how Marc plans to take it forward, including: 

  • The takeover of Recipharm by EQT, a global investment organisation with a “passion for future-proofing companies” 
  • Focus on operational excellence, meeting the needs unmet by the competition, emerging technologies, and innovation 
  • Opportunities in the areas of small molecules, biologics, and North America 
  • Recipharm’s and EQT’s “priority 1” – customer focus 
  • Affordable and safe drugs 
  • How Recipharm are operating during the COVID-19 pandemic 
  • What Marc sees as his biggest challenges, both now and in the future 

Watch: Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Download Request

PharmaVentures InSights: The impact of conference cancellations on dealmaking during the Covid-19 pandemic

Can Partnering Conference Cancellations Affect Dealmaking in 2020?

We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we overcome the current global health challenge, how do you make sure your opportunities are still getting in front of your potential partners. 
PharmaVentures has been successfully connecting buyers and sellers for over 28 years with and without partnering conferences. PharmaVentures’ CEO, Dr. Fintan Walton talks about how PharmaVentures is continuing a business as usual approach for all of our clients.